Anti-SARS-CoV-2 antibodies derived from 2DD8

An antibody or an antigen-binding fragment that selectively binds to a SARS-CoV-2, that comprises:

• (i) a VH CDR1 having an amino acid sequence of SEQ ID NO:
• 58, a VH CDR2 having an amino acid sequence of SEQ ID NO:
• 104, a VH CDR3 having an amino acid sequence of SEQ ID NO:
• 153, a VL CDR1 having an amino acid sequence of SEQ ID NO:
• 3, a VL CDR2 having an amino acid sequence of SEQ ID NO:
• 6, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
• 14;
• (ii) a VH CDR1 having an amino acid sequence of SEQ ID NO:
• 83, a VH CDR2 having an amino acid sequence of SEQ ID NO:
• 129, a VH CDR3 having an amino acid sequence of SEQ ID NO:
• 178, a VL CDR1 having an amino acid sequence of SEQ ID NO:
• 3, a VL CDR2 having an amino acid sequence of SEQ ID NO:
• 6, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
• 39;
• (iii) a VH CDR1 having an amino acid sequence of SEQ ID NO:
• 57, a VH CDR2 having an amino acid sequence of SEQ ID NO:
• 103, a VH CDR3 having an amino acid sequence of SEQ ID NO:
• 152, a VL CDR1 having an amino acid sequence of SEQ ID NO:
• 3, a VL CDR2 having an amino acid sequence of SEQ ID NO:
• 8, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
• 13;
• or
• (iv) a VH CDR1 having an amino acid sequence of SEQ ID NO:
• 76, a VH CDR2 having an amino acid sequence of SEQ ID NO:
• 122, a VH CDR3 having an amino acid sequence of SEQ ID NO:
• 171, a VL CDR1 having an amino acid sequence of SEQ ID NO:
• 3, a VL CDR2 having an amino acid sequence of SEQ ID NO:
• 6, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
• 32.